[
  {
    "ts": "2026-02-11T05:03:17+00:00",
    "headline": "Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ...",
    "summary": "Gilead Sciences Inc (GILD) reports robust HIV sales growth and outlines strategic initiatives for 2026, despite facing competitive pressures in cell therapy.",
    "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-q4-050317430.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "d070589a-bdcb-3265-9aa6-e7e12145708f",
      "content": {
        "id": "d070589a-bdcb-3265-9aa6-e7e12145708f",
        "contentType": "STORY",
        "title": "Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ...",
        "description": "",
        "summary": "Gilead Sciences Inc (GILD) reports robust HIV sales growth and outlines strategic initiatives for 2026, despite facing competitive pressures in cell therapy.",
        "pubDate": "2026-02-11T05:03:17Z",
        "displayTime": "2026-02-11T05:03:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-q4-050317430.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-q4-050317430.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T11:29:00+00:00",
    "headline": "These Stocks Are Today’s Movers: Moderna, Robinhood, Cloudflare, Humana, Lyft, Mattel, Beta Technologies, Gilead, and More",
    "summary": "Shares in Moderna tumble after the company says the Food and Drug Administration refuses to review a seasonal flu vaccine application.",
    "url": "https://www.barrons.com/articles/stock-movers-93fe9143?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "d3c99806-d7e1-34e8-bfb0-e54d087fa7b0",
      "content": {
        "id": "d3c99806-d7e1-34e8-bfb0-e54d087fa7b0",
        "contentType": "STORY",
        "title": "These Stocks Are Today’s Movers: Moderna, Robinhood, Cloudflare, Humana, Lyft, Mattel, Beta Technologies, Gilead, and More",
        "description": "",
        "summary": "Shares in Moderna tumble after the company says the Food and Drug Administration refuses to review a seasonal flu vaccine application.",
        "pubDate": "2026-02-11T11:29:00Z",
        "displayTime": "2026-02-11T11:29:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/d3c99806-d7e1-34e8-bfb0-e54d087fa7b0/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/dfc369dfc75a1f0587c152e0f813ca6b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Uo8UTy_QlezfC1z9StNeHg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/dfc369dfc75a1f0587c152e0f813ca6b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ONvzJWyntskVEcsn7C5YpA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/dfc369dfc75a1f0587c152e0f813ca6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-93fe9143?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "NET"
            },
            {
              "symbol": "HUM"
            },
            {
              "symbol": "LYFT"
            },
            {
              "symbol": "MAT"
            },
            {
              "symbol": "BETA"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "F"
            },
            {
              "symbol": "MSTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T13:11:15+00:00",
    "headline": "Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target",
    "summary": "Analysts said that Yeztugo’s forecast, which would represent 433% year-over-year growth, is achievable.",
    "url": "https://www.pharmaceutical-technology.com/news/gilead-expects-6-of-hiv-sales-growth-in-2026-with-800m-yeztugo-target/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "7f0786c8-c750-349b-82ef-85bb53367c42",
      "content": {
        "id": "7f0786c8-c750-349b-82ef-85bb53367c42",
        "contentType": "STORY",
        "title": "Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target",
        "description": "",
        "summary": "Analysts said that Yeztugo’s forecast, which would represent 433% year-over-year growth, is achievable.",
        "pubDate": "2026-02-11T13:11:15Z",
        "displayTime": "2026-02-11T13:11:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/1db1c3e83813b81d49aca3c27c4493dc",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1Y5V775AIXbWVCye1ufgUQ--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/1db1c3e83813b81d49aca3c27c4493dc.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4l7z8DxoVKdOd_no6.6g4A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/1db1c3e83813b81d49aca3c27c4493dc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/gilead-expects-6-of-hiv-sales-growth-in-2026-with-800m-yeztugo-target/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-expects-6-hiv-sales-131115397.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T12:41:00+00:00",
    "headline": "These Stocks Are Today’s Movers: Moderna, Robinhood, Shopify, Kraft Heinz, Cloudflare, Humana, Lyft, Mattel, Beta Tech, and More",
    "summary": "Shares in Moderna tumble after the company says the Food and Drug Administration refuses to review a seasonal flu vaccine application.",
    "url": "https://www.barrons.com/articles/stock-movers-93fe9143?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "d3c99806-d7e1-34e8-bfb0-e54d087fa7b0",
      "content": {
        "id": "d3c99806-d7e1-34e8-bfb0-e54d087fa7b0",
        "contentType": "STORY",
        "title": "These Stocks Are Today’s Movers: Moderna, Robinhood, Shopify, Kraft Heinz, Cloudflare, Humana, Lyft, Mattel, Beta Tech, and More",
        "description": "",
        "summary": "Shares in Moderna tumble after the company says the Food and Drug Administration refuses to review a seasonal flu vaccine application.",
        "pubDate": "2026-02-11T12:41:00Z",
        "displayTime": "2026-02-11T12:41:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/d3c99806-d7e1-34e8-bfb0-e54d087fa7b0/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/dfc369dfc75a1f0587c152e0f813ca6b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Uo8UTy_QlezfC1z9StNeHg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/dfc369dfc75a1f0587c152e0f813ca6b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ONvzJWyntskVEcsn7C5YpA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/dfc369dfc75a1f0587c152e0f813ca6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-93fe9143?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "BETA"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "SHOP"
            },
            {
              "symbol": "KHC"
            },
            {
              "symbol": "NET"
            },
            {
              "symbol": "HUM"
            },
            {
              "symbol": "LYFT"
            },
            {
              "symbol": "MAT"
            },
            {
              "symbol": "MSTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T05:31:16+00:00",
    "headline": "GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook",
    "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of $29.8 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $1.86 per share was 1.9% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/gild-q4-deep-dive-hiv-053116371.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "9978ebad-31d0-335c-9efc-7ab5df86798f",
      "content": {
        "id": "9978ebad-31d0-335c-9efc-7ab5df86798f",
        "contentType": "STORY",
        "title": "GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook",
        "description": "",
        "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of $29.8 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $1.86 per share was 1.9% above analysts’ consensus estimates.",
        "pubDate": "2026-02-11T05:31:16Z",
        "displayTime": "2026-02-11T05:31:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "GILD Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7IhZSScYZ4CvnQJJpve_Dg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cv.0mSrHV7hG2Zeh2xc10A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gild-q4-deep-dive-hiv-053116371.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gild-q4-deep-dive-hiv-053116371.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T15:17:07+00:00",
    "headline": "Gilead Bounds Higher As Analysts Debate The Future Of Its Potential HIV Blockbuster",
    "summary": "Gilead stock reversed higher Wednesday after beating fourth-quarter expectations and issuing strong guidance for Yeztugo.",
    "url": "https://www.investors.com/news/technology/gilead-stock-gilead-sciences-earnings-q4-2025/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "1b616d78-4f60-39cd-9f96-6ceb8e28749c",
      "content": {
        "id": "1b616d78-4f60-39cd-9f96-6ceb8e28749c",
        "contentType": "STORY",
        "title": "Gilead Bounds Higher As Analysts Debate The Future Of Its Potential HIV Blockbuster",
        "description": "",
        "summary": "Gilead stock reversed higher Wednesday after beating fourth-quarter expectations and issuing strong guidance for Yeztugo.",
        "pubDate": "2026-02-11T15:17:07Z",
        "displayTime": "2026-02-11T15:17:07Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1b616d78-4f60-39cd-9f96-6ceb8e28749c/gilead-bounds-higher-as.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/c41f2b75ef43110c88cfcb472262eb79",
          "originalWidth": 945,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/shVGxj7bu_u.CpYzNTXRdw--~B/aD01MzM7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/c41f2b75ef43110c88cfcb472262eb79.cf.webp",
              "width": 945,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WU5OlgKO09tNMial_TfFPA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/c41f2b75ef43110c88cfcb472262eb79.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/gilead-stock-gilead-sciences-earnings-q4-2025/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]